Key takeaways
- PT-141 is the code name for bremelanotide, a synthetic peptide developed from melanotan II.
- It activates several melanocortin receptors, including the one that controls skin pigment.
- In the US it is the active ingredient of Vyleesi, a prescription medicine approved in 2019 for one diagnosed condition in premenopausal women. Products sold online as “PT-141” are not that medicine.
- In the phase-3 trials of the approved medicine, 18% of participants who received it stopped because of side effects, against 2% on placebo.
- Its label lists nausea in 4 in 10 trial participants who received it, a short rise in blood pressure after each dose, and dark patches on the skin or gums whose fading was not confirmed in every case. It is ruled out for people with uncontrolled high blood pressure or known cardiovascular disease.
01What it is
PT-141 is the code name for bremelanotide, a small ring-shaped synthetic peptide that activates several melanocortin receptors, including the one that controls skin pigment (MC1R). It was developed from melanotan II and differs from it at one end of the molecule.
| Property | Detail |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Size | Seven amino acids, six of them closed into a ring |
| Molecular formula | C₅₀H₆₈N₁₄O₁₀ |
| Receptor activity | Not selective. Potency order in the label: MC1R, then MC4R, MC3R, MC5R and MC2R |
| Closest relative | Melanotan II: the same ring, but it ends in an amide (C₅₀H₆₉N₁₅O₉) where bremelanotide ends in a free acid |
Two other melanocortin-receptor agonists, afamelanotide and setmelanotide, are authorised medicines in the EU for different conditions.
02Regulatory status, Nov 2026
In the US, bremelanotide is the active ingredient of Vyleesi, a prescription medicine approved in 2019 for one diagnosed condition in premenopausal women. Its label says it is not indicated for men or for women after menopause. The label also states that how it works in that condition is not known.
Research-grade material is not that medicine
Products sold online as “PT-141” are not that medicine. In August 2026, FDA warning letters to three online sellers listed their “PT-141”, labelled for research use, among unapproved new drugs.
| Where | Status |
|---|---|
| United States | Active ingredient of Vyleesi (NDA 210557, approved June 2019). In August 2026, FDA warning letters to three online sellers listed “PT-141” sold for research use among unapproved new drugs. |
| European Union | No EU-wide authorisation. The EMA’s list of centrally authorised medicines includes no bremelanotide medicine (checked 17 Nov 2026). |
| United Kingdom | The UK electronic medicines compendium (emc) returned no bremelanotide medicine (searched 17 Nov 2026). |
| Anti-doping (WADA) | Bremelanotide is not named on WADA’s Prohibited List for 2026 or 2027. Athletes in tested sport should check the status of any substance with their national anti-doping organisation, and products sold online may not contain what the label says. |
Checked 17 Nov 2026. Next check due by 15 Feb 2027.
03What the label lists
The approved medicine’s label lists a short rise in blood pressure after each dose, nausea in 4 in 10 trial participants who received it, flushing, headache, and dark patches on the skin or gums whose fading was not confirmed in every case. The label rules it out for people with uncontrolled high blood pressure or known cardiovascular disease, and does not recommend it for people at high cardiovascular risk. In the phase-3 trials, 18% of participants who received it stopped because of side effects, against 2% on placebo. These figures come from trials of the regulated medicine and do not describe products sold online.
Blood pressure
Systolic pressure rose by up to 6 mmHg and diastolic by up to 3 mmHg after each dose, peaking at 2 to 4 hours, and heart rate fell by up to 5 beats per minute. Values usually returned to baseline within 12 hours.
Skin and gum pigment
Dark patches on the face, gums or breasts: 1% in the phase-3 trials, none on placebo, and 38% in a separate study where it was given every day for 8 days. More likely with darker skin. Fading was not confirmed in every case.
Liver, other medicines, pregnancy
One case of acute hepatitis in the open-label extension of the phase-3 trials, where a role for the drug could not be excluded. It may slow stomach emptying, which can reduce absorption of oral medicines, and it may significantly lower blood levels of oral naltrexone, a combination the label says to avoid. Animal studies showed harm to the fetus.
| Reported in the phase-3 trials | Medicine | Placebo |
|---|---|---|
| Nausea | 40% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection-site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
04What the research hasn’t shown
- That products sold online as “PT-141” contain what their label says.
This content is educational. It is not medical advice and does not describe use in humans. If you have a health condition, consult a licensed clinician who knows you.
05Sources
- FDA. Vyleesi (bremelanotide injection) prescribing information, revised 10/2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s…
- FDA. Drugs@FDA, NDA 210557 (Vyleesi), approved 21 June 2019. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=o…
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 2006;27(4):921–930. doi.org/10.1016/j.peptides.2005.01.029
- PubChem. Bremelanotide, CID 9941379 (melanotan II: CID 92432). pubchem.ncbi.nlm.nih.gov/compound/9941379
- European Medicines Agency. Centrally authorised medicines, data export dated 17 November 2026. www.ema.europa.eu/en/medicines
- FDA. Warning letter 734884, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-crimin…
- FDA. Warning letter 733652, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-crimin…
- FDA. Warning letter 735067, 24 August 2026. www.fda.gov/inspections-compliance-enforcement-and-crimin…
- World Anti-Doping Agency. Prohibited List 2026, and Prohibited List 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list